CY1116006T1 - Η εξουδετερωση της δρασtικοτητας των cd95 διακοπτει τη διηθηση των κυτταρων γλοιοβλαστωματος in vivo - Google Patents

Η εξουδετερωση της δρασtικοτητας των cd95 διακοπτει τη διηθηση των κυτταρων γλοιοβλαστωματος in vivo

Info

Publication number
CY1116006T1
CY1116006T1 CY20151100106T CY151100106T CY1116006T1 CY 1116006 T1 CY1116006 T1 CY 1116006T1 CY 20151100106 T CY20151100106 T CY 20151100106T CY 151100106 T CY151100106 T CY 151100106T CY 1116006 T1 CY1116006 T1 CY 1116006T1
Authority
CY
Cyprus
Prior art keywords
vivo
cells
activity
stoppes
glioplastoma
Prior art date
Application number
CY20151100106T
Other languages
Greek (el)
English (en)
Inventor
Ana Martin-Villalba
Susanne Kleber
Benedikt Wiestler
Peter G Krammer
Christel Herold-Mende
Ignacio Sancho-Martinez
Original Assignee
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts filed Critical Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
Publication of CY1116006T1 publication Critical patent/CY1116006T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20151100106T 2006-12-28 2015-02-02 Η εξουδετερωση της δρασtικοτητας των cd95 διακοπτει τη διηθηση των κυτταρων γλοιοβλαστωματος in vivo CY1116006T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87736706P 2006-12-28 2006-12-28
EP20110190918 EP2428252B1 (en) 2006-12-28 2007-12-28 Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo

Publications (1)

Publication Number Publication Date
CY1116006T1 true CY1116006T1 (el) 2017-01-25

Family

ID=39400900

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100106T CY1116006T1 (el) 2006-12-28 2015-02-02 Η εξουδετερωση της δρασtικοτητας των cd95 διακοπτει τη διηθηση των κυτταρων γλοιοβλαστωματος in vivo

Country Status (12)

Country Link
US (2) US9309320B2 (enExample)
EP (2) EP2428252B1 (enExample)
JP (2) JP5558828B2 (enExample)
AU (1) AU2007341631B9 (enExample)
CA (1) CA2673868C (enExample)
CY (1) CY1116006T1 (enExample)
DK (2) DK2101877T3 (enExample)
ES (2) ES2523992T3 (enExample)
PL (2) PL2428252T3 (enExample)
PT (2) PT2428252E (enExample)
SI (1) SI2428252T1 (enExample)
WO (1) WO2008080623A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963124C (en) 2007-07-10 2019-10-15 Apogenix Ag Tnf superfamily collectin fusion proteins
EP2318441A2 (en) * 2008-07-14 2011-05-11 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
US8664366B2 (en) 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
EP2456468A1 (en) * 2009-07-21 2012-05-30 Queen Mary and Westfield College Fas (apo-1, cd95) targeted platforms for intracellular drug delivery
EP2322927A1 (en) * 2009-11-16 2011-05-18 Deutsches Krebsforschungszentrum Compounds inhibiting CD95 signaling for the treatment of pancreatic cancer
HK1207095A1 (en) * 2012-07-18 2016-01-22 阿珀吉尼科斯股份公司 Composition comprising a mixture of cd95-fc isoforms
EP2894472A4 (en) * 2012-09-05 2016-03-30 Jsr Corp METHOD OF SCREENING MATERIAL FOR EPITHELIAL CONSERVATION OF CELLS
BR112015027249A2 (pt) * 2013-04-29 2017-09-26 Apogenix Gmbh método de diagnóstico de câncer
US20160115237A1 (en) 2013-05-24 2016-04-28 The University Of British Columbia Cell senescence markers as diagnostic and therapeutic targets
EP3094744A1 (en) * 2014-01-15 2016-11-23 Apogenix AG Method of predicting the responsiveness of a cancer disease to treatment on the basis of dna methylation
EP3137909B1 (en) * 2014-04-29 2018-06-06 Apogenix AG Diagnostic anti-cd95l antibody
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
AU2019403393A1 (en) * 2018-12-20 2021-08-05 The University Of Chicago Methods and compositions related to therapeutic peptides for cancer therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891434A (en) 1991-06-17 1999-04-06 Centocor, Inc. Monoclonal antibodies to the APO-1 antigen
CA2109398A1 (en) 1992-10-30 1994-05-01 Alejandro A. Aruffo Extracellular matrix receptor ligands that modulate leukocyte function
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
DE4447484C2 (de) 1994-04-08 1997-07-17 Deutsches Krebsforsch Mittel zur Hemmung von Apoptose
US6060238A (en) * 1995-02-13 2000-05-09 The Regents Of The University Of Michigan Method and composition for regulating apoptosis
DE69636170T2 (de) 1995-03-20 2006-11-02 Okumura, Ko Monoklonaler antikörper, der spezifisch mit dem fas-liganden reagiert, und verfahren zu seiner herstellung
JP3925663B2 (ja) 1995-06-30 2007-06-06 持田製薬株式会社 抗Ｆａｓリガンド抗体および該抗体を用いた測定法
JPH09124509A (ja) 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
ATE299936T1 (de) 1996-05-02 2005-08-15 Mochida Pharm Co Ltd Fas antigen-derivate
EP1642908A2 (en) 1996-09-02 2006-04-05 Okumura, Ko Apoptosis-induced site from fas ligand
ATE393222T1 (de) 1997-09-18 2008-05-15 Genentech Inc Dcr3 polypeptid, ein tnfr homolog
CA2324517A1 (en) 1998-03-30 1999-10-07 Eli Lilly And Company Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the tnf receptor superfamily
US6348573B1 (en) * 1998-04-27 2002-02-19 The Regents Of The University Of Michigan Compositions and methods for identifying apoptosis signaling pathway inhibitors and activators
US6846637B1 (en) 1998-06-18 2005-01-25 Imed Ab Fas peptides and antibodies for modulating apoptosis
US20030170244A1 (en) * 2001-12-21 2003-09-11 Pluenneke John D. Inhibition of Fas signaling
WO2003088975A1 (en) * 2002-04-17 2003-10-30 The Burnham Institute Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
JP2007533595A (ja) * 2003-03-26 2007-11-22 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウィルス感染の治療
US7445794B1 (en) * 2004-04-29 2008-11-04 The Regents Of The University Of Colorado Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors

Also Published As

Publication number Publication date
SI2428252T1 (sl) 2015-01-30
WO2008080623A3 (en) 2008-09-12
PT2101877E (pt) 2013-07-22
US9309320B2 (en) 2016-04-12
JP5558828B2 (ja) 2014-07-23
WO2008080623A2 (en) 2008-07-10
JP2010514722A (ja) 2010-05-06
EP2101877B1 (en) 2013-06-19
AU2007341631B2 (en) 2012-08-30
US9850308B2 (en) 2017-12-26
US20160115236A1 (en) 2016-04-28
ES2523992T3 (es) 2014-12-03
DK2101877T3 (da) 2013-09-23
JP5893078B2 (ja) 2016-03-23
AU2007341631B9 (en) 2012-10-04
CA2673868C (en) 2016-03-22
JP2014167024A (ja) 2014-09-11
PL2101877T3 (pl) 2013-11-29
AU2007341631A1 (en) 2008-07-10
ES2420582T3 (es) 2013-08-26
EP2428252B1 (en) 2014-11-05
EP2101877A2 (en) 2009-09-23
US20100322922A1 (en) 2010-12-23
DK2428252T3 (en) 2015-02-16
CA2673868A1 (en) 2008-07-10
PL2428252T3 (pl) 2015-04-30
EP2428252A1 (en) 2012-03-14
PT2428252E (pt) 2014-12-11

Similar Documents

Publication Publication Date Title
CY1116006T1 (el) Η εξουδετερωση της δρασtικοτητας των cd95 διακοπτει τη διηθηση των κυτταρων γλοιοβλαστωματος in vivo
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1116797T1 (el) Αναστολεις φωσφοϊνοσιτιδιου 3-κινασης με ενα τμημα δεσμευσης ψευδαργυρου
EP2590671A4 (en) IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAIN AND USES THEREOF
CY1119213T1 (el) Πρωτεϊνη p75ntr συνδεσης νευροτροφινης για θεραπευτικη χρηση
CY1118452T1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
MX2013002270A (es) Inmonoglubinas de dominio variable doble y usos de las mismas.
IN2012DN02521A (enExample)
MX2011011670A (es) Inmunoglobulinas de dominio variable dual y usos de las mismas.
CY1120434T1 (el) Πρωτεϊνες προσδεσης il-1
CY1118349T1 (el) Παραγοντες συνδεσης me cd19 και χρησεις αυτων
MX2011008221A (es) Tratamiento de cancer de pulmon con un compuesto de nitrobenzamida en combinacion con un inhibidor de un factor de crecimieno.
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
UA108832C2 (uk) Комбінації кон'югата анти-her2-антитіло-лікарський засіб і хіміотерапевтичних засобів і способи застосування
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
MX2012005037A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
PH12012502523A1 (en) Dual variable domain immunoglobulins and uses thereof
CY1116195T1 (el) Παραγοντες δεσμευσης του notch 1 υποδοχεα και μεθοδοι χρησης αυτων
MX2011006685A (es) Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
MX374896B (es) Compuestos con actividad anticáncer.
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
PH12013501127A1 (en) Use of sigma ligands in bone cancer pain
WO2011121453A3 (en) Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
MX2011004085A (es) Factores sanguineos modificados que comprenden un bajo grado de polimero soluble en agua.